EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The N-terminal region of malaria vaccine candidate asparagine-rich merozoite antigen is immunodominant and targeted by polyreactive antibodies

Rolando Garza iD, Jeffrey M Marchioni, Jared D Honeycutt, Nicholas K Hurlburt, Caroline Torres, Anakaren Garcia, Siddharth Neog, Eva Loranc, Emily Yemington, Dalton Towers, Isaac Ssewanyana, Marie Pancera und 5 weitere

Disease Models & Mechanisms · 01.05.2026 · 19 (5)

DOI: 10.1242/dmm.052979 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Disease Models & Mechanisms, online erschienen am 02.06.2026. Verfasst von Rolando Garza und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology & Molecular Genetics, University of Texas at San Antonio Health Science Center, San Antonio, TX 78229, USA. Hauptthemen laut MEDLINE: Antigens, Protozoan, Malaria Vaccines, Antibodies, Protozoan, Asparagine. Die Arbeit nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Institute of Allergy and Infectious Diseases, NIAID NIH HHS, NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The development of malaria blood-stage vaccines has been hampered by sequence variation in many Plasmodium falciparum proteins involved in erythrocyte invasion. In the past few years, asparagine-rich merozoite antigen (PfARMA) has emerged as a potential vaccine candidate due to its low amino acid sequence diversity and the association between anti-PfARMA antibody levels and protection from malaria. Here, we used samples from P. falciparum-exposed individuals to study naturally acquired B cell and antibody responses to PfARMA. B cell responses to PfARMA were dominated by IgM+ B cells that recognized the N-terminal intrinsically disordered region 1 (IDR1) of PfARMA. A human monoclonal antibody (hmAb) to IDR1 was non-neutralizing, while a second hmAb binding to the folded domain showed weak neutralizing activity. Both PfARMA-specific plasma IgM and IgG responses predominately targeted IDR1, and their levels increased with P. falciparum exposure. However, in contrast to previous reports, these antibody responses did not correlate with protection in age- and exposure-matched children. Interestingly, approximately 30% of unexposed individuals had IgG that also targeted IDR1 and was polyreactive, binding to regions with high asparagine content. Finally, we determined that PfARMA is located in or near micronemes that contain erythrocyte binding antigen 175 (PfEBA-175). These data suggest that while IgG to the folded domain of PfARMA may inhibit parasite growth, antibody responses to PfARMA are primarily directed to IDR1. Consequently, these responses may reflect recent exposure rather than contributing to functional immunity to malaria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antigens, ProtozoanMalaria VaccinesAntibodies, ProtozoanAsparagineMerozoitesImmunodominant EpitopesHumansPlasmodium falciparumB-LymphocytesAntibodies, MonoclonalAntibody SpecificityMalaria, FalciparumImmunoglobulin MImmunoglobulin GAmino Acid Sequence

Stichwörter der Autor:innen

AutoantibodiesB cellsInhibitionInvasionMalariaMonoclonal antibodiesPolyreactivity

Substanzen

Antigens, ProtozoanMalaria VaccinesAntibodies, ProtozoanAsparagineImmunodominant EpitopesAntibodies, MonoclonalImmunoglobulin MImmunoglobulin G

Autor:innen und Institutionen

  • Department of Microbiology, Immunology & Molecular Genetics, University of Texas at San Antonio Health Science Center, San Antonio, TX 78229, USA.
  • Department of Biomedical Engineering, University of Texas at Austin, Austin, TX 78712, USA.
  • Department of Medicine, University of California San Francisco, San Francisco, CA 94158, USA.
  • Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
  • Infectious Disease Research Collaboration, Kampala, Uganda.
  • Department of Chemical Engineering, University of Texas at Austin, Austin, TX 78712, USA.

ORCID-Profile: Rolando Garza, Evelien M Bunnik

Förderung

  • National Institute of Allergy and Infectious Diseases
  • NIAID NIH HHS
  • NIH HHS
  • University of Texas Health Science Center at San Antonio
  • Max and Minnie Tomerlin Voelcker Fund
  • National Institutes of Health

Zitieren

APA

Garza, R., Marchioni, J. M., Honeycutt, J. D., Hurlburt, N. K., Torres, C., Garcia, A., Neog, S., Loranc, E., Yemington, E., Towers, D., Ssewanyana, I., Pancera, M., Lavinder, J. J., Jagannathan, P., Greenhouse, B., Bol, S., & Bunnik, E. M. (2026). The N-terminal region of malaria vaccine candidate asparagine-rich merozoite antigen is immunodominant and targeted by polyreactive antibodies. Disease Models & Mechanisms, 19(5). https://doi.org/10.1242/dmm.052979

Vancouver

Garza R, Marchioni JM, Honeycutt JD, Hurlburt NK, Torres C, Garcia A, et al. The N-terminal region of malaria vaccine candidate asparagine-rich merozoite antigen is immunodominant and targeted by polyreactive antibodies. Disease Models & Mechanisms. 2026;19(5). doi:10.1242/dmm.052979

BibTeX
@article{Garza2026,
  author = {Garza, Rolando and Marchioni, Jeffrey M and Honeycutt, Jared D and Hurlburt, Nicholas K and Torres, Caroline and Garcia, Anakaren and Neog, Siddharth and Loranc, Eva and Yemington, Emily and Towers, Dalton and Ssewanyana, Isaac and Pancera, Marie and Lavinder, Jason J and Jagannathan, Prasanna and Greenhouse, Bryan and Bol, Sebastiaan and Bunnik, Evelien M},
  title = {The N-terminal region of malaria vaccine candidate asparagine-rich merozoite antigen is immunodominant and targeted by polyreactive antibodies},
  journal = {Disease Models & Mechanisms},
  year = {2026},
  volume = {19},
  number = {5},
  doi = {10.1242/dmm.052979}
}
Kostenlos starten →